Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy.
about
Atacicept: targeting B cells in multiple sclerosisMolecular markers in oral lichen planus: A systematic reviewIK acts as an immunoregulator of inflammatory arthritis by suppressing TH17 cell differentiation and macrophage activationB cell antigen presentation promotes Th2 responses and immunopathology during chronic allergic lung diseaseA quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacyNovel applications of Rituximab in dermatological disordersGenome-wide DNA methylation profiling in rheumatoid arthritis identifies disease-associated methylation changes that are distinct to individual T- and B-lymphocyte populations.Significance of intragraft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies.In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles.Recent developments in the immunobiology of rheumatoid arthritisInterleukin-32-induced thymic stromal lymphopoietin plays a critical role in macrophage differentiation through the activation of caspase-1 in vitro.B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management.Towards understanding the pathology of erythema nodosum leprosum.Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical responseNon-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.TSPAN33 is a novel marker of activated and malignant B cells.Autoantibodies to posttranslational modifications in rheumatoid arthritis.Rituximab: a review of dermatological applications.Emerging cell and cytokine targets in rheumatoid arthritis.Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study.Vitamin D Deficiency and Rheumatoid Arthritis.Efficient B cell depletion via diphtheria toxin in CD19-Cre/iDTR mice.Drug-Target Kinetics in Drug Discovery.Relationship between NK Cell Activation and Clinical Response in Rheumatoid Arthritis Treated with Rituximab.Genome-wide profiling in treatment-naive early rheumatoid arthritis reveals DNA methylome changes in T and B lymphocytes.NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab.Inhibition of B-cell apoptosis is mediated through increased expression of Bcl-2 in patients with rheumatoid arthritis.B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis.
P2860
Q24628925-BF54D748-A439-48D1-B97C-D75E773E42A8Q26748536-0773A01C-9882-4419-A788-D84EDF45E4ABQ28817694-EDD8EB4E-1B1D-42EA-8E32-E3A5747A252CQ33366487-AD03DFE6-29B5-4D85-B560-C0E2FFF4163EQ33636442-26D3620F-D708-403F-B85C-BED3E5878BD8Q34087599-7429C90D-F068-41B4-A9A2-9B384D646450Q34212663-A2016244-008C-47B9-A431-44D9AAA4D3FEQ34222399-B5980ADA-FE8D-4904-AF40-76731A5A290CQ36477500-12EE198A-B308-490D-8920-6A17AACE96C1Q36757047-F5F4DB2E-1340-46A3-9772-70184AE12418Q36907662-C84EB835-010D-4B4C-9CF6-B024D97865FDQ36924505-1FBEDB90-4AE6-4E3B-A8AA-0EAAA6E06D99Q37060528-616F3486-D078-4180-9C0B-D7BE84C177F8Q37099759-9CB6CB8A-448E-4B55-A1AC-C6920786894AQ37350904-DC5A0302-51D8-48F1-B8B1-322AA54FC8E5Q37350960-97B00EDD-065D-44BC-B7F5-4A1C4CE8F43DQ37388213-88DE8E01-5B3F-43E6-BECA-C6639A756F66Q37640818-78E39C7C-8008-44D3-B829-32737B8B29E4Q37693939-A899BC2C-C3EF-4502-A3CE-D7C78A37CC10Q37781697-E33E86D3-28E0-47C3-9117-ED8099AC759BQ38161794-50753D73-6B7F-463D-84D2-98A39ABFC34DQ38274496-1DB8A2F3-500C-490B-9578-2B92E63C5D2FQ38916397-C007065C-8AD1-4406-96D4-1F845D74B043Q39353665-8993FB05-BCE3-43BE-915A-FE95A285FFFBQ39391104-369E8073-F934-4114-AE1F-9BFDA83BE5A7Q39530138-D4D12CBF-8419-4FBD-BE6B-4F82FA36FB27Q40335127-D1C5AD37-E933-41E6-AEFC-D13423B166FCQ42020570-CE21E114-2960-43C9-8DE7-106A8FD712D1Q52661869-11239234-EFB6-4632-8FC0-B2A95558A74AQ53082574-0484AAA0-4EE8-45BD-BD76-6C35446CF78F
P2860
Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Immunopathologic role of B lym ...... le of B cell-directed therapy.
@ast
Immunopathologic role of B lym ...... le of B cell-directed therapy.
@en
type
label
Immunopathologic role of B lym ...... le of B cell-directed therapy.
@ast
Immunopathologic role of B lym ...... le of B cell-directed therapy.
@en
prefLabel
Immunopathologic role of B lym ...... le of B cell-directed therapy.
@ast
Immunopathologic role of B lym ...... le of B cell-directed therapy.
@en
P2093
P1433
P1476
Immunopathologic role of B lym ...... le of B cell-directed therapy.
@en
P2093
Hans-Peter Brezinschek
Lorena Martinez-Gamboa
Thomas Dörner
P304
P356
10.1016/J.AUTREV.2006.02.004
P577
2006-03-09T00:00:00Z